There is a shortage of the immediate release formulation of Adderall, which is used to treat attention-deficit/hyperactivity disorder (ADHD), according to the Food and Drug Administration (FDA).
Teva Pharmaceuticals, which manufactures the medication containing amphetamine mixed salts, is having intermittent manufacturing delays that could last until March 2023.
Other manufacturers produce similar medications but not in sufficient supply for U.S. demand. The FDA suggested patients may consider extended-release versions of the medication and work with their health care provider to find the best treatment option during the shortage. For more information on which manufacturers have similar products available, visit https://bit.ly/3extN3y.
The AAP has guidance on medications for ADHD in its Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.